MicroRNA-340-5p suppresses non-small cell lung cancer cell growth and metastasis by targeting ZNF503

[1]  J. Zhao,et al.  Kaempferol suppresses proliferation but increases apoptosis and autophagy by up-regulating microRNA-340 in human lung cancer cells. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Xiaoping Zhou,et al.  Lower miR-340 expression predicts poor prognosis of non-small cell lung cancer and promotes cell proliferation by targeting CDK4. , 2018, Gene.

[3]  Hongming Song,et al.  MicroRNA-340 inhibits invasion and metastasis by downregulating ROCK1 in breast cancer cells , 2017, Oncology letters.

[4]  P. Li,et al.  MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma , 2017, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[5]  H. Juan,et al.  Erratum: Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer , 2017, Oncogene.

[6]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[7]  Wan-xin Wu,et al.  MiR-340 suppresses cell migration and invasion by targeting MYO10 in breast cancer. , 2016, Oncology reports.

[8]  Yuxin Tang,et al.  MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway. , 2016, Oncology reports.

[9]  B. Qiao,et al.  microRNA-340 Suppresses Tumorigenic Potential of Prostate Cancer Cells by Targeting High-Mobility Group Nucleosome-Binding Domain 5. , 2016, DNA and cell biology.

[10]  H. Juan,et al.  Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer , 2015, Oncogene.

[11]  S. Ohue,et al.  miR340 suppresses the stem-like cell function of glioma-initiating cells by targeting tissue plasminogen activator. , 2015, Cancer research.

[12]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[13]  Payam Shahi,et al.  The Transcriptional Repressor ZNF503/Zeppo2 Promotes Mammary Epithelial Cell Proliferation and Enhances Cell Invasion* , 2014, The Journal of Biological Chemistry.

[14]  P. Verde,et al.  miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer , 2014, Oncogene.

[15]  George A Calin,et al.  Tumour angiogenesis regulation by the miR-200 family , 2013, Nature Communications.

[16]  D De Ruysscher,et al.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  F. Slack,et al.  Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Ming Yi,et al.  Human glioma growth is controlled by microRNA-10b. , 2011, Cancer research.

[19]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Robert A. Weinberg,et al.  Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model , 2010, Nature Biotechnology.

[21]  Douglas D Boyd,et al.  Unbiased Screening for Transcriptional Targets of ZKSCAN3 Identifies Integrin β4 and Vascular Endothelial Growth Factor as Downstream Targets* , 2008, Journal of Biological Chemistry.

[22]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[23]  Douglas D Boyd,et al.  The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. , 2008, Cancer research.

[24]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[25]  R. Govindan,et al.  Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[27]  Yu Ding,et al.  ZNF 503 promotes colon cancer cell proliferation and mediates tumor progression via activating Myc , 2017 .

[28]  C. Gridelli,et al.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[30]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[31]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.